TTCR Improvement Tafenoquine v Placebo
Simulated survival curve of sustained 4-day recovery from acute COVID-19 symptoms in the subset of non-hospitalized high and low risk patients enrolled in NCT04533347 with at least two moderate COVID symptoms randomized to receive tafenoquine or placebo (post hoc endpoint).
Format
JPEG
Source
Sixty Degrees Pharmaceuticals